
Articles
-
3 weeks ago |
news-decoder.com | Susan Ruel
We seem to be leaping ahead in cancer prevention and treatment. But will that be only for those who can pay? A doctor prepares a cervical exam.
-
Feb 13, 2025 |
univadis.es | Susan Ruel
Editado por la Dra. Susan RuelCONCLUSIÓN PRÁCTICAAgregar daratumumab al tratamiento de mantenimiento con lenalidomida después del trasplante en los pacientes con mieloma múltiple triplica la tasa de conversión de enfermedad residual mínima a negativa al 50,5 % frente al 18,8 % con lenalidomida sola. Con el tratamiento combinado se reduce el riesgo de progresión en un 47 % y se logran tasas estimadas de supervivencia libre de progresión a 30 meses del 82,7 % frente al 66,4 % con lenalidomida sola.
-
Jan 23, 2025 |
mdedge.com | Susan Ruel
TOPLINE:The analysis of 11,427 US Deparment of Veterans Affairs (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 years in patients with severely low absolute lymphocyte count vs 4.2 years in those with normal counts.
-
Jan 16, 2025 |
mdedge.com | Susan Ruel
TOPLINE:In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free survival of 11 months. Longer initial therapy duration and greater time gap between treatments were associated with superior outcomes.
-
Jan 16, 2025 |
mdedge.com | Susan Ruel
TOPLINE:CD37, a surface protein present on most acute myeloid leukemia (AML) blasts, demonstrates unique internalization properties that enable targeted drug delivery with minimal impact on normal blood cells. Anti-CD37 antibody-drug conjugate (ADC) shows specific cytotoxicity to AML blasts while preserving normal hematopoietic stem cells.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →